1. Home
  2. Animal Drug Index - V
  3. Vetameg

Animal NDC 46066-503-01 Vetameg

Flunixin Meglumine

Animal Product Information

Field Name Field Value
Animal NDC Code 46066-503-01
Proprietary Name Vetameg What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
Non-Proprietary Name Flunixin Meglumine What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
Labeler Name Aspen Veterinary Resources
Product Type Prescription Animal Drug
Active Ingredient(s)
  • Flunixin Meglumine
Marketing Category ANADA - ABBREVIATED NEW ANIMAL DRUG APPLICATION What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
FDA Application Number ANADA200581 What is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.

Vetameg Images

Vetameg Animal Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Table of Contents



Warnings And Precautions



VetaMeg® Equine Paste
(flunixin meglumine paste)

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION: Each 30-g syringe of VetaMeg Equine Paste contains flunixin meglumine equivalent to 1500 mg flunixin.

INDICATIONS: VetaMeg Equine Paste is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse.

ACTIVITY: Flunixin meglumine is a potent, nonnarcotic, nonsteroidal analgesic agent with anti-inflammatory and antipyretic activity, It is significantly more potent than pentazocine, meperidine, and codeine as an analgesic in the rat yeast paw test. Oral studies in the horse show onset of flunixin activity occurs withing 2 hours of administration. Peak response occurs between 12 and 16 hours and duration of activity is 24-36 hours.

CONTRAINDICATIONS: There are no known contraindications to this drug when used as directed.

WARNING: Do not use in horses intended for human consumption.

PRECAUTIONS: The effect of flunixin meglumine on pregnancy has not been determined. Studies to date show there is no detrimental effect on stallion spermatogenesis with or following the recommended dose of flunixin meglumine.

SIDE EFFECTS: During field studies with flunixin meglumine, no significant side effects were reported.

To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Aspen Veterinary Resources at [email protected]. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov/reportanimalae.


Dosage & Administration



DOSAGE AND ADMINISTRATION: The recommended dose of flunixin meglumine is 0.5 mg per lb of body weight once daily. The VetaMeg Equine Paste syringe, calibrated in twelve 250-lb weight increments, delivers 125 mg of flunixin for each 250 lbs (see dosage table). One syringe will treat a 1000-lb horse once daily for 3 days, or three 1000-lb horses one time.

DOSAGE TABLE

 Syringe Mark* Horse Weight (lbs) VetaMeg™ Equine Paste Delevered (g)mg Flunixin Delivered 
 0 --- --- ---
 250 250 2.5 125
 500 500 5.0 250
 750 750 7.5 375
 1000 1000 10.0 500

* Use dial edge nearest syringe barrel to mark dose.

The paste is orally administered by inserting the nozzle of the syringe through the interdental space, and depositing the required amount of paste on the back of the tongue by depressing the plunger.

Treatment may be given initially by intravenous or intramuscular injection of VetaMeg Injectable Solution, followed by VetaMeg Equine Paste on Days 2 to 5. Flunixin meglumine treatment should not exceed 5 consecutive days.

TOXICITY: No toxic effects were observed in rats given oral flunixin meglumine 2 mg/kg per day for 42 days. Higher doses produced ulceration of the gastrointestinal tract. The emetic dose in dogs is between 150 and 250 mg/kg. Flunixin was well tolerated in monkeys dosed daily with 4 mg/kg for 56 days. No adverse effects occurred in horses dosed orally with 1.0 or 1.5 mg/lb for 5 consecutive days.


Storage And Handling



Store at 20°C - 25°C (68°F - 77°F); excursions permitted between 15°C - 30°C (between 59°F - 86°F)

See product information sheet for additional information.

Approved by FDA under ANADA # 200-581


* The information on this page is for an ANIMAL PRODUCT, please review the complete disclaimer below.